EP4048709C0 - Arzneimittel zur behandlung von gebärmutterhalskrebs - Google Patents

Arzneimittel zur behandlung von gebärmutterhalskrebs

Info

Publication number
EP4048709C0
EP4048709C0 EP21840418.4A EP21840418A EP4048709C0 EP 4048709 C0 EP4048709 C0 EP 4048709C0 EP 21840418 A EP21840418 A EP 21840418A EP 4048709 C0 EP4048709 C0 EP 4048709C0
Authority
EP
European Patent Office
Prior art keywords
medicines
treatment
cervical cancer
cervical
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP21840418.4A
Other languages
English (en)
French (fr)
Other versions
EP4048709A4 (de
EP4048709B1 (de
EP4048709A1 (de
Inventor
Mevlude Canlica
Mehmet Rifki Topcul
Idil Cetin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yildiz Teknik Universitesi
Original Assignee
Yildiz Teknik Universitesi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yildiz Teknik Universitesi filed Critical Yildiz Teknik Universitesi
Publication of EP4048709A4 publication Critical patent/EP4048709A4/de
Publication of EP4048709A1 publication Critical patent/EP4048709A1/de
Application granted granted Critical
Publication of EP4048709C0 publication Critical patent/EP4048709C0/de
Publication of EP4048709B1 publication Critical patent/EP4048709B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21840418.4A 2020-12-29 2021-05-31 Arzneimittel zur behandlung von gebärmutterhalskrebs Active EP4048709B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2020/22158A TR202022158A1 (tr) 2020-12-29 2020-12-29 Rahim ağzı kanseri tedavisi için bir ilaç.
PCT/TR2021/050515 WO2022146292A1 (en) 2020-12-29 2021-05-31 A drug for the treatment of cervical cancer

Publications (4)

Publication Number Publication Date
EP4048709A4 EP4048709A4 (de) 2022-08-31
EP4048709A1 EP4048709A1 (de) 2022-08-31
EP4048709C0 true EP4048709C0 (de) 2025-02-26
EP4048709B1 EP4048709B1 (de) 2025-02-26

Family

ID=80784998

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21840418.4A Active EP4048709B1 (de) 2020-12-29 2021-05-31 Arzneimittel zur behandlung von gebärmutterhalskrebs

Country Status (3)

Country Link
EP (1) EP4048709B1 (de)
TR (1) TR202022158A1 (de)
WO (1) WO2022146292A1 (de)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3617135B2 (ja) * 1995-08-28 2005-02-02 三菱化学株式会社 フタロシアニン化合物及びそれを用いた光学記録媒体

Also Published As

Publication number Publication date
EP4048709A4 (de) 2022-08-31
EP4048709B1 (de) 2025-02-26
EP4048709A1 (de) 2022-08-31
WO2022146292A1 (en) 2022-07-07
TR202022158A1 (tr) 2022-07-21

Similar Documents

Publication Publication Date Title
EP4473970A4 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren
EP3634417C0 (de) Chinazolin-pyrazolderivate zur behandlung von krebsbedingten erkrankungen
EP4017489C0 (de) Dgd1202 zur behandlung von kras-mutierten krebsen
EP3862000C0 (de) Arzneimittel zur behandlung von chronischem husten
EP4359405A4 (de) Beta-lactam-derivate zur behandlung von krankheiten
EP3988102C0 (de) Arzneimittel zur vorbeugung oder behandlung von rhinovirusinfektionen
EP4392423A4 (de) Chinazolinverbindungen zur behandlung von krankheiten
EP4055033A4 (de) Kombinationstherapie zur behandlung von hirnkrebs
EP4419504A4 (de) Kdm1a-hemmer zur behandlung von krankheiten
EP4000609A4 (de) Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von knochenerkrankungen
EP3488850A4 (de) Neuartige verwendung von gzd824 und pharmazeutisch akzeptable salze davon zur behandlung von krankheiten
EP4215531A4 (de) Verbindung zur prävention und behandlung von lebererkrankungen und pharmazeutische verwendung davon
EP3600324A4 (de) Arzneimittel und zusammensetzungen zur behandlung von augenkrankheiten
EP3958863C0 (de) Neuartige verbindungen und pharmazeutische zusammensetzungen daraus zur behandlung von nierenerkrankungen
EP4467140A4 (de) Pharmazeutische kombination zur behandlung von tumoren und verwendung davon
EP4129291A4 (de) Arzneimittel zur behandlung von coronavirusinfektionen
EP3672593C0 (de) Arzneimittel zur behandlung von gefässverengenden erkrankungen oder störungen
EP4422608A4 (de) Endoxifen zur behandlung von krebs
EP4196167A4 (de) Nanoteilchenförmiges system zur behandlung von mundkrebs
EP3654979A4 (de) Verwendung von wx-uk1 und seinem prodrug, wx-671, zur behandlung von nichtkrebsartigen erkrankungen
EP4157246C0 (de) Therapeutische kombination zur behandlung von brustkrebs
EP4197554A4 (de) Kombiniertes medikament zur behandlung von weichgewebesarkom
EP3834834C0 (de) Arzneimittel zur behandlung von gewebenekrose oder zur verbesserung der herzfunktion
EP4048709C0 (de) Arzneimittel zur behandlung von gebärmutterhalskrebs
EP4512401A4 (de) Arzneimittel zur behandlung oder prävention von krebs

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220120

A4 Supplementary search report drawn up and despatched

Effective date: 20220801

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240717

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20241108

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602021026897

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20250226

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI

Effective date: 20250306

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 5

Effective date: 20250515

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250526

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250626

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250526

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250527

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250226

REG Reference to a national code

Ref country code: CH

Ref legal event code: H13

Free format text: ST27 STATUS EVENT CODE: U-0-0-H10-H13 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251223

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250531

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20250531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250226

26N No opposition filed

Effective date: 20251127